001     301576
005     20250819100457.0
024 7 _ |a 10.1038/s41467-025-59979-6
|2 doi
024 7 _ |a pmid:40413188
|2 pmid
024 7 _ |a altmetric:177391069
|2 altmetric
037 _ _ |a DKFZ-2025-01084
041 _ _ |a English
082 _ _ |a 500
100 1 _ |a Zanti, Maria
|0 0000-0002-0136-9921
|b 0
245 _ _ |a Analysis of more than 400,000 women provides case-control evidence for BRCA1 and BRCA2 variant classification.
260 _ _ |a [London]
|c 2025
|b Springer Nature
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1755590655_6402
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
500 _ _ |a Hamann, Ute: Molecular Genetics of Breast Cancer, German Cancer Research Center (DKFZ),
520 _ _ |a Clinical genetic testing identifies variants causal for hereditary cancer, information that is used for risk assessment and clinical management. Unfortunately, some variants identified are of uncertain clinical significance (VUS), complicating patient management. Case-control data is one evidence type used to classify VUS. As an initiative of the Evidence-based Network for the Interpretation of Germline Mutant Alleles (ENIGMA) Analytical Working Group we analyze germline sequencing data of BRCA1 and BRCA2 from 96,691 female breast cancer cases and 302,116 controls from three studies: the BRIDGES study of the Breast Cancer Association Consortium, the Cancer Risk Estimates Related to Susceptibility consortium, and the UK Biobank. We observe 11,207 BRCA1 and BRCA2 variants, with 6909 being coding, covering 23.4% of BRCA1 and BRCA2 VUS in ClinVar and 19.2% of ClinVar curated (likely) benign or pathogenic variants. Case-control likelihood ratio (ccLR) evidence is highly consistent with ClinVar assertions for (likely) benign or pathogenic variants; exhibiting 99.1% sensitivity and 95.3% specificity for BRCA1 and 93.3% sensitivity and 86.6% specificity for BRCA2. This approach provides case-control evidence for 787 unclassified variants; these include 579 with strong or moderate benign evidence and 10 with strong pathogenic evidence for which ccLR evidence is sufficient to alter clinical classification.
536 _ _ |a 313 - Krebsrisikofaktoren und Prävention (POF4-313)
|0 G:(DE-HGF)POF4-313
|c POF4-313
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a BRCA2 Protein
|2 NLM Chemicals
650 _ 7 |a BRCA1 Protein
|2 NLM Chemicals
650 _ 7 |a BRCA2 protein, human
|2 NLM Chemicals
650 _ 7 |a BRCA1 protein, human
|2 NLM Chemicals
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Female
|2 MeSH
650 _ 2 |a Case-Control Studies
|2 MeSH
650 _ 2 |a BRCA2 Protein: genetics
|2 MeSH
650 _ 2 |a Breast Neoplasms: genetics
|2 MeSH
650 _ 2 |a BRCA1 Protein: genetics
|2 MeSH
650 _ 2 |a Genetic Predisposition to Disease
|2 MeSH
650 _ 2 |a Genetic Testing
|2 MeSH
650 _ 2 |a Germ-Line Mutation
|2 MeSH
650 _ 2 |a Middle Aged
|2 MeSH
700 1 _ |a O'Mahony, Denise G
|0 0000-0002-7212-0920
|b 1
700 1 _ |a Parsons, Michael T
|0 0000-0003-3242-8477
|b 2
700 1 _ |a Dorling, Leila
|b 3
700 1 _ |a Dennis, Joe
|0 0000-0003-4591-1214
|b 4
700 1 _ |a Boddicker, Nicholas J
|b 5
700 1 _ |a Chen, Wenan
|0 0000-0003-0379-2368
|b 6
700 1 _ |a Hu, Chunling
|0 0000-0002-6814-4639
|b 7
700 1 _ |a Naven, Marc
|b 8
700 1 _ |a Yiangou, Kristia
|b 9
700 1 _ |a Ahearn, Thomas U
|0 0000-0003-0771-7752
|b 10
700 1 _ |a Ambrosone, Christine B
|0 0000-0003-1717-9943
|b 11
700 1 _ |a Andrulis, Irene L
|0 0000-0002-4226-6435
|b 12
700 1 _ |a Antoniou, Antonis C
|b 13
700 1 _ |a Auer, Paul L
|0 0000-0003-1735-8044
|b 14
700 1 _ |a Baynes, Caroline
|b 15
700 1 _ |a Bodelon, Clara
|0 0000-0002-6578-2678
|b 16
700 1 _ |a Bogdanova, Natalia V
|b 17
700 1 _ |a Bojesen, Stig E
|0 0000-0002-4061-4133
|b 18
700 1 _ |a Bolla, Manjeet K
|0 0000-0002-4351-9326
|b 19
700 1 _ |a Brantley, Kristen D
|0 0000-0003-0084-4775
|b 20
700 1 _ |a Camp, Nicola J
|b 21
700 1 _ |a Campbell, Archie
|0 0000-0003-0198-5078
|b 22
700 1 _ |a Castelao, Jose E
|b 23
700 1 _ |a Cessna, Melissa H
|b 24
700 1 _ |a Chang-Claude, Jenny
|0 P:(DE-He78)c259d6cc99edf5c7bc7ce22c7f87c253
|b 25
700 1 _ |a Chen, Fei
|b 26
700 1 _ |a Chenevix-Trench, Georgia
|b 27
700 1 _ |a NBCS Collaborators
|b 28
|e Collaboration Author
700 1 _ |a Conroy, Don M
|b 29
700 1 _ |a Czene, Kamila
|b 30
700 1 _ |a De Nicolo, Arcangela
|0 0000-0002-7275-5571
|b 31
700 1 _ |a Domchek, Susan M
|b 32
700 1 _ |a Dörk, Thilo
|0 0000-0002-9458-0282
|b 33
700 1 _ |a Dunning, Alison M
|0 0000-0001-6651-7166
|b 34
700 1 _ |a Eliassen, A Heather
|0 0000-0002-3961-6609
|b 35
700 1 _ |a Evans, D Gareth
|0 0000-0002-8482-5784
|b 36
700 1 _ |a Fasching, Peter A
|0 0000-0003-4885-8471
|b 37
700 1 _ |a Figueroa, Jonine D
|0 0000-0002-5100-623X
|b 38
700 1 _ |a Flyger, Henrik
|b 39
700 1 _ |a Gago-Dominguez, Manuela
|b 40
700 1 _ |a García-Closas, Montserrat
|b 41
700 1 _ |a Glendon, Gord
|b 42
700 1 _ |a González-Neira, Anna
|b 43
700 1 _ |a Grassmann, Felix
|b 44
700 1 _ |a Hadjisavvas, Andreas
|b 45
700 1 _ |a Haiman, Christopher A
|0 0000-0002-0097-9971
|b 46
700 1 _ |a Hamann, Ute
|0 P:(DE-He78)537e07b3e57b16c7b214fc2242e4326b
|b 47
700 1 _ |a Hart, Steven N
|0 0000-0001-7714-2734
|b 48
700 1 _ |a Hartman, Mikael B A
|b 49
700 1 _ |a Ho, Weang-Kee
|0 0000-0002-8269-7344
|b 50
700 1 _ |a Hodge, James M
|b 51
700 1 _ |a Hoppe, Reiner
|0 0000-0003-2213-9612
|b 52
700 1 _ |a Howell, Sacha J
|0 0000-0001-8141-6515
|b 53
700 1 _ |a Investigators, kConFab
|b 54
|e Collaboration Author
700 1 _ |a Jakubowska, Anna
|0 0000-0002-5650-0501
|b 55
700 1 _ |a Khusnutdinova, Elza K
|b 56
700 1 _ |a Ko, Yon-Dschun
|b 57
700 1 _ |a Kraft, Peter
|0 0000-0002-4472-8103
|b 58
700 1 _ |a Kristensen, Vessela N
|0 0000-0001-5012-7438
|b 59
700 1 _ |a Lacey, James V
|b 60
700 1 _ |a Li, Jingmei
|0 0000-0001-8587-7511
|b 61
700 1 _ |a Lim, Geok Hoon
|0 0000-0002-5296-3437
|b 62
700 1 _ |a Lindström, Sara
|b 63
700 1 _ |a Lophatananon, Artitaya
|b 64
700 1 _ |a Luccarini, Craig
|b 65
700 1 _ |a Mannermaa, Arto
|b 66
700 1 _ |a Martinez, Maria Elena
|b 67
700 1 _ |a Mavroudis, Dimitrios
|b 68
700 1 _ |a Milne, Roger L
|0 0000-0001-5764-7268
|b 69
700 1 _ |a Muir, Kenneth
|0 0000-0001-6429-988X
|b 70
700 1 _ |a Nathanson, Katherine L
|0 0000-0002-6740-0901
|b 71
700 1 _ |a Nuñez-Torres, Rocio
|b 72
700 1 _ |a Obi, Nadia
|b 73
700 1 _ |a Olson, Janet E
|0 0000-0003-4944-7789
|b 74
700 1 _ |a Palmer, Julie R
|b 75
700 1 _ |a Panayiotidis, Mihalis I
|0 0000-0002-1450-3552
|b 76
700 1 _ |a Patel, Alpa V
|b 77
700 1 _ |a Pharoah, Paul D P
|0 0000-0001-8494-732X
|b 78
700 1 _ |a Polley, Eric C
|b 79
700 1 _ |a Rashid, Muhammad U
|0 0000-0002-7684-3122
|b 80
700 1 _ |a Ruddy, Kathryn J
|0 0000-0001-6298-332X
|b 81
700 1 _ |a Saloustros, Emmanouil
|0 0000-0002-0485-0120
|b 82
700 1 _ |a Sawyer, Elinor J
|0 0000-0001-8285-4111
|b 83
700 1 _ |a Schmidt, Marjanka K
|0 0000-0002-2228-429X
|b 84
700 1 _ |a Southey, Melissa C
|0 0000-0002-6313-9005
|b 85
700 1 _ |a Tan, Veronique Kiak-Mien
|b 86
700 1 _ |a Teo, Soo Hwang
|0 0000-0002-0444-590X
|b 87
700 1 _ |a Teras, Lauren R
|0 0000-0003-2419-8536
|b 88
700 1 _ |a Torres, Diana
|b 89
700 1 _ |a Trentham-Dietz, Amy
|b 90
700 1 _ |a Truong, Thérèse
|0 0000-0002-2943-6786
|b 91
700 1 _ |a Vachon, Celine M
|0 0000-0002-1962-9322
|b 92
700 1 _ |a Wang, Qin
|b 93
700 1 _ |a Weitzel, Jeffrey N
|0 0000-0001-6714-092X
|b 94
700 1 _ |a Yadav, Siddhartha
|0 0000-0003-4630-9903
|b 95
700 1 _ |a Yao, Song
|0 0000-0001-9442-1313
|b 96
700 1 _ |a Zirpoli, Gary R
|0 0000-0003-1417-5349
|b 97
700 1 _ |a Cline, Melissa S
|b 98
700 1 _ |a Devilee, Peter
|0 0000-0002-8023-2009
|b 99
700 1 _ |a Tavtigian, Sean V
|0 0000-0002-7543-8221
|b 100
700 1 _ |a Goldgar, David E
|b 101
700 1 _ |a Couch, Fergus J
|0 0000-0001-9417-9985
|b 102
700 1 _ |a Easton, Douglas F
|0 0000-0003-2444-3247
|b 103
700 1 _ |a Spurdle, Amanda B
|0 0000-0003-1337-7897
|b 104
700 1 _ |a Michailidou, Kyriaki
|0 0000-0001-7065-1237
|b 105
700 1 _ |a KristensenChenevix-Trench, Vessela NGeorgia
|b 106
|e Contributor
773 _ _ |a 10.1038/s41467-025-59979-6
|g Vol. 16, no. 1, p. 4852
|0 PERI:(DE-600)2553671-0
|n 1
|p 4852
|t Nature Communications
|v 16
|y 2025
|x 2041-1723
909 C O |p VDB
|o oai:inrepo02.dkfz.de:301576
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 25
|6 P:(DE-He78)c259d6cc99edf5c7bc7ce22c7f87c253
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 47
|6 P:(DE-He78)537e07b3e57b16c7b214fc2242e4326b
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-313
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Krebsrisikofaktoren und Prävention
|x 0
914 1 _ |y 2025
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b NAT COMMUN : 2022
|d 2025-01-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2025-01-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2025-01-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2024-01-30T07:48:07Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2024-01-30T07:48:07Z
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Peer review
|d 2024-01-30T07:48:07Z
915 _ _ |a Creative Commons Attribution CC BY (No Version)
|0 LIC:(DE-HGF)CCBYNV
|2 V:(DE-HGF)
|b DOAJ
|d 2024-01-30T07:48:07Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2025-01-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1040
|2 StatID
|b Zoological Record
|d 2025-01-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1060
|2 StatID
|b Current Contents - Agriculture, Biology and Environmental Sciences
|d 2025-01-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1150
|2 StatID
|b Current Contents - Physical, Chemical and Earth Sciences
|d 2025-01-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
|d 2025-01-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2025-01-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2025-01-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1190
|2 StatID
|b Biological Abstracts
|d 2025-01-02
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2025-01-02
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2025-01-02
915 _ _ |a IF >= 15
|0 StatID:(DE-HGF)9915
|2 StatID
|b NAT COMMUN : 2022
|d 2025-01-02
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2025-01-02
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2025-01-02
920 1 _ |0 I:(DE-He78)C020-20160331
|k C020
|l Epidemiologie von Krebs
|x 0
920 1 _ |0 I:(DE-He78)B072-20160331
|k B072
|l Molekulargenetik des Mammakarzinoms
|x 1
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)C020-20160331
980 _ _ |a I:(DE-He78)B072-20160331
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21